ImmVira Pharma Co. Ltd Report issue

For profit Phase 1 Phase 2
Founded: Shenzhen China (2015)

Organization Overview

First Clinical Trial
2020
NCT05602792
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

ImmVira Pharma Co. Ltd

Active Ingredients

Drugs in Phase 2 Trials (3)

cobimetinib (cotellic) (1 trial)

pembrolizumab (keytruda) (1 trial)

t3011 (5 trials)

Drugs in Phase 1 Trials (1)

c5252 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Skin Neoplasms (Phase 1)

Soft Tissue Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 4